Association of time-to-treatment with outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients

Table 5 Clinical factors affecting hospital mortality

	Univariable			Multivariable^†
	Crude OR	95% CI	P value	Adjusted OR	95% CI	P value
Age	1.06	1.01–1.10	0.011	1.07	1.01–1.14	0.034
Gender	0.43	0.12–1.50	0.184	0.80	0.10–6.06	0.826
SAPS 3	1.05	1.00–1.10	0.033	1.05	0.98–1.13	0.149
Serum albumin, g/dL	0.47	0.18–1.26	0.133	0.58	0.13–2.56	0.469
Cytomegalovirus co-infection	5.50	1.44–20.96	0.013	3.19	0.52–19.63	0.212
Bacterial co-infection	3.65	0.82–16.19	0.089	2.90	0.34–24.32	0.327
Time to anti-PCP treatment, hour	1.00	0.99–1.01	0.939	1.01	0.99–1.02	0.307
Failure to initial treatment	8.38	2.36–29.74	0.001	14.12	2.23–89.38	0.005

OR odds ratio, CI confidence interval, SAPS Simplified Acute Physiology Score 3, PCP Pneumocystis pneumonia

ISSN: 1465-993X